TLR2 and neoplasm: Particularly, they developed a novel TLR2-L called Amplivant (AV)(ISA Pharmaceuticals, Leiden, Oegstgeest, The Netherlands) and reported a strong potency of AV-SLP conjugates in inducing DC maturation, in vivo T cell priming, and anti-tumor immunity, which correlated well with the therapeutic effect in a murine tumor model [151].